Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

Movement Disorders

Volumn 32, Issue 9, 2017, Pages 1264-1310

  Obeso, J A ^a,b,c   Stamelou, M ^d,e   Goetz, C G ^f   Poewe, W ^g   Lang, A E ^h,i   Weintraub, D ^j,k   Burn, D ^l   Halliday, G M ^m,n   Bezard, E ^o,p   Przedborski, S ^q   Lehericy, S ^r,s   Brooks, D J ^l,t   Rothwell, J C ^u   Hallett, M ^v   DeLong, M R ^w   Marras, C ^x   Tanner, C M ^k,y   Ross, G W ^k   Langston, J W ^z   Klein, C ^aa   Bonifati, V ^ab   Jankovic, J ^ac   Lozano, A M ^x   Deuschl, G ^ad   Bergman, H ^ae,af,ag   Tolosa, E ^ah,ai   Rodriguez Violante, M ^aj,ak   Fahn, S ^al   Postuma, R B ^am   Berg, D ^an   Marek, K ^ao   Standaert, D G ^ap   Surmeier, D J ^aq   Olanow, C W ^ar   Kordower, J H ^f   Calabresi, P ^as,at   Schapira, A H V ^au   Stoessl, A J ^av,aw   more..

^a HOSPITAL DE MÓSTOLES   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF ATHENS   (Greece)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h TORONTO WESTERN HOSPITAL   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^o UNIVERSITÉ DE BORDEAUX   (France)

^p INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^q Columbia University ^*  (United States)

^r SORBONNE UNIVERSITÉ   (France)

^s PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^t AARHUS UNIVERSITY   (Denmark)

^u UNIVERSITY COLLEGE LONDON   (United Kingdom)

^v NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^w EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x UNIVERSITY OF TORONTO   (Canada)

^y UNIVERSITY OF CALIFORNIA   (United States)

^z PARKINSON S INSTITUTE   (United States)

^aa UNIVERSITY OF LÜBECK   (Germany)

^ab ERASMUS MEDICAL CENTER   (Netherlands)

^ac BAYLOR COLLEGE OF MEDICINE   (United States)

^ad UNIVERSITY OF KIEL   (Germany)

^ae HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^af HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^ag HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^ah HOSPITAL CLÍNIC   (Spain)

^ai UNIVERSITY OF BARCELONA   (Spain)

^aj Movement Disorders Clinic   (Mexico)

^ak NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^al Department of Medicine   (United States)

^am MONTREAL GENERAL HOSPITAL   (Canada)

^an UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^ao INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^ap University of Alabama at Birmingham   (United States)

^aq NORTHWESTERN UNIVERSITY   (United States)

^ar MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^as UNIVERSITY OF PERUGIA   (Italy)

^at IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^au UNIVERSITY COLLEGE LONDON   (United Kingdom)

^av UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^aw VANCOUVER COASTAL HEALTH   (Canada)

more..

Author keywords

200 years anniversary; Parkinson's disease; Shaking Palsy

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; VACUOLAR PROTEIN SORTING 35 HOMOLOG;

BASAL GANGLION; BRADYKINESIA; CLINICAL FEATURE; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG SCREENING; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; FUNCTIONAL NEUROIMAGING; FUTUROLOGY; GAIT; GENE MUTATION; HISTORY; HUMAN; LEWY BODY; MENTAL DISEASE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RIGIDITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SYMPTOM; TREMOR;

ANNIVERSARIES AND SPECIAL EVENTS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PARKINSON DISEASE;

EID: 85028967067     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27115     Document Type: Review

References (299)

1. Goldman JG, Goetz CG. History of Parkinson's disease. Handb Clin Neurol 2007;83:107-128.
2. Parkinson J, Hunter J. Hunterian Reminiscences; Being the Substance of a Course of Lectures on the Principles and Practice of Surgery, Delivered by J. Hunter, in the Year 1785. London: Sherwood, Gilbert, and Piper 1833.
3. Parkinson J. The Villager's Friend and Physician. London: C Whittingham 1804.
4. Parkinson J. Dangerous Sports: A Tale. London: HD Symonds 1807.
5. Parkinson J. Some account of the effects of lightning. Mem M Soc Lon 1789;2:490-500.
6. Parkinson J. Observations on the Nature and Cure of Gout. London: HD Symonds 1805.
7. Parkinson J, Parkinson J. On the treatment of infectious or typhoid fever. Lond Med Repository 1824;1:197.
8. Parkinson J. Organic Remains of a Former World. An Examination of the Mineralized Remains of the Vegetables and Animals of the Antediluian World; Generally Termed Extraneous Fossils. London 1833.
9. Parkinson J. An Essay on the Shaking Palsy. London: Whittingham and Rowland Sherwood, Neely and Jones 1817.
10. Herzberg L. An essay on the shaking palsy: reviews and notes on the journals in which they appeared. Mov Disord 1990;5(2):162-166.
11. Burrows G, Thomson A. Editor's note. Lond Med Repository 1817;8:59-61.
12. Louis ED. The shaking palsy, the first forty-five years: a journey through the British literature. Mov Disord 1997;12(6):1068-1072.
13. Fahn S, Goetz CG. Charcot, the clinician: the Tuesday lessons: excerpts from nine case presentations on general neurology delivered at the Salpêtrière Hospital in 1887-88 by Jean-Martin Charcot. Mov Disord 1987;4(1):123-140.
14. Charcot JM. Lectures on the Diseases of the Nervous System, Delivered at La Salpêtrière. London: The New Sydenham Society 1877.
15. Stern G. Did parkinsonism occur before 1817? J Neurol Neurosurg Psychiatry 1989;52(suppl.):11-12.
16. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51(6):745-752.
17. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30(12):1591-1601.
18. Horowski R, Horowski L, Phil C, Vogel S, Poewe W, Kielhorn FW. An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. Neurology 1995;45(3):565-568.
19. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PDStudy). Mov Disord 2015;30(2):229-237.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17(5):427-427.
21. Gowers WR. A Manual of Diseases of the Nervous System. London: J. & A. Churchill 1886.
22. Schwab RS, Doshay LJ, Garland H, Bradshaw P, Garvey E, Crawford B. Shift to older age distribution in parkinsonism: a report on 1,000 patients covering the past decade from three centers. Neurology 1956;6(11):783-790.
23. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004;55(6):761-765.
24. Lang AE. A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 2011;26(5):775-783.
25. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007;130(8):2123-2128.
26. Nutt JG. Motor subtype in Parkinson's disease: different disorders or different stages of disease? Mov Disord 2016;31(7):957-961.
27. Marras C, Chaudhuri KR. Nonmotor features of Parkinson's disease subtypes. Mov Disord 2016;31(8):1095-1102.
28. Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. PLoS ONE 2013;8(8):e70244.
29. Fereshtehnejad S-M, Romenets SR, Anang JBM, Latreille V, Gagnon J-F, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression. JAMA Neurol 2015;72(8):863-873.
30. Nalls MA, Escott-Price V, Williams NM, et al. Genetic risk and age in Parkinson's disease: continuum not stratum. Mov Disord 2015;30(6):850-854.
31. Guella I, Evans DM, Szu-Tu C, et al. α-synuclein genetic variability: a biomarker for dementia in Parkinson disease. Ann Neurol 2016;79(6):991-999.
32. Espay AJ, Brundin P, Lang AE. Precision medicine for disease modification in Parkinson disease. Nat Rev Neurol 2017;13(2):119-126.
33. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 2016;86(6):566-576.
34. Boeve BF, Dickson DW, Duda JE, et al. Arguing against the proposed definition changes of PD. Mov Disord 2016;31(11):1619-1622.
35. Postuma RB, Berg D, Stern M, et al. Abolishing the 1-year rule: how much evidence will be enough? Mov Disord 2016;31(11):1623-1627.
36. Batla A, Erro R, Stamelou M, et al. Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Mov Disord 2014;29(14):1820-1825.
37. Wile DJ, Dinelle K, Vafai N, et al. A scan without evidence is not evidence of absence: scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. Mov Disord 2016;31(3):405-409.
38. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80(5):496-503.
39. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71(9):670-676.
40. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47(1):1-9.
41. Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014;29(14):1758-1766.
42. Mestre TA, Gupta A, Lang AE. MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category. J Neurol Neurosurg Psychiatry 2016;87(4):443-444.
43. Brigo F, Erro R, Marangi A, Bhatia K, Tinazzi M. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014;20(8):808-814.
44. Vizcarra JA, Lang AE, Sethi KD, Espay AJ. Vascular parkinsonism: deconstructing a syndrome. Mov Disord 2015;30(7):886-894.
45. Magdalinou NK, Ling H, Smith JDS, Schott JM, Watkins LD, Lees AJ. Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series. J Neurol 2013;260(4):1009-1013.
46. Ahmed RM, Murphy E, Davagnanam I, et al. A practical approach to diagnosing adult onset leukodystrophies. J Neurol Neurosurg Psychiatry 2014;85(7):770-881.
47. Weintraub D, Burn DJ. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26(6):1022-1031.
48. Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease: the ICICLE-PD study. Neurology 2013;80(3):276-281.
49. Hoogland J, Boel JA, de Bie RMA. Mild cognitive impairment as a risk factor for Parkinson's disease dementia [published online ahead of print 2017]. Mov Disord.
50. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 2015;30(12):1600-1611.
51. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56(6):730-736.
52. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27(3):349-356.
53. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351(24):2509-2518.
54. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2008;72(10):886-892.
55. Richard I, McDermott M, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson's disease. Neurology 2012;78:1229-1236.
56. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168(10):1066-1074.
57. Fénelon G, Soulas T, Zenasni F, de Langavant LC. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 2010;25(6):763-766.
58. Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord 2016;31:45-52.
59. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383:533-540.
60. Weintraub D, Koester J, Potenza M, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-595.
61. Krack P, Martinez-Fernandez R, del Alamo M, Obeso JA. Current applications and limitations of surgical treatments for movement disorders. Mov Disord 2017;32(1):36-52.
62. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson Disease. Arch Neurol 2010;67(1):58-63.
63. Parent M, Parent A. Substantia nigra and Parkinson's disease: a brief history of their long and intimate relationship. Can J Neurol Sci 2010;37(03):313-319.
64. Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 2014;30(1):4-18.
65. Hall H, Reyes S, Landeck N, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain 2014;137(9):2493-2508.
66. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8(12):1150-1157.
67. Iacono D, Geraci-Erck M, Rabin ML, et al. Parkinson disease and incidental Lewy body disease: just a question of time? Neurology 2015;85(19):1670-1679.
68. Michel PP, Hirsch EC, Hunot S. Understanding dopaminergic cell death pathways in Parkinson disease. Neuron 2016;90(4):675-691.
69. Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JPA. Environmental risk factors and Parkinson's disease: an umbrella review of meta-analyses. Parkinsonism Relat Disord 2016;23:1-9.
70. Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease. Mov Disord 2015;30(11):1442-1450.
71. Doherty KM, Silveira-Moriyama L, Parkkinen L, et al. Parkin disease: a clinicopathologic entity? JAMA Neurology 2013;70(5):571-579.
72. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011;122(2):187-204.
73. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol 1988;7(6):299-305.
74. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.
75. McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and braak hypothesis. Mov Disord 2015;31(2):152-160.
76. Carlsson A, Lindqvist M, Magnusson TOR. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180(4596):1200.
77. Ungerstedt U. 6-hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968;5(1):107-110.
78. Langston J, Ballard P, Tetrud J, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219(4587):979-980.
79. Polymeropoulos MH. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 1997;276(5321):2045-2047.
80. Feany MB, Bender WW. A drosophila model of Parkinson's disease. Nature 2000;404(6776):394-398.
81. Masliah E. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287(5456):1265-1269.
82. Ekstrand MI, Terzioglu M, Galter D, et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 2007;104(4):1325-1330.
83. Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338(6109):949-953.
84. Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014;75(3):351-362.
85. Schon EA, Przedborski S. Mitochondria: the next (neurode) generation. Neuron 2011;70(6):1033-1053.
86. Visanji NP, Brotchie JM, Kalia LV, et al. α-synuclein-based animal models of Parkinson's disease: challenges and opportunities in a new era. Trends Neurosci 2016;39(11):750-762.
87. Brundin P, Atkin G, Lamberts JT. Basic science breaks through: New therapeutic advances in Parkinson's disease. Mov Disord 2015;30(11):1521-1527.
88. Martin WRW, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: A potential biomarker of disease status. Neurology 2008;70(Pt 2):1411-1417.
89. Schwarz ST, Abaei M, Gontu V, Morgan PS, Bajaj N, Auer DP. Diffusion tensor imaging of nigral degeneration in Parkinson's disease: a region-of-interest and voxel-based study at 3T and systematic review with meta-analysis. NeuroImage Clin 2013;3:481-488.
90. Ofori E, Pasternak O, Planetta PJ, et al. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. Brain 2015;138(8):2322-2331.
91. Sharman M, Valabregue R, Perlbarg V, et al. Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. Mov Disord 2012;28(4):447-454.
92. Kwon D-H, Kim J-M, Oh S-H, et al. Seven-tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71(2):267-277.
93. Castellanos G, Fernández-Seara MA, Lorenzo-Betancor O, et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov Disord 2015;30(7):945-952.
94. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133(11):3423-3433.
95. Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ. Resting state functional connectivity of the striatum in Parkinson's disease. Brain 2012;135(12):3699-3711.
96. Esposito F, Tessitore A, Giordano A, et al. Rhythm-specific modulation of the sensorimotor network in drug-naïve patients with Parkinson's disease by levodopa. Brain 2013;136(3):710-725.
97. Szewczyk-Krolikowski K, Menke RAL, Rolinski M, et al. Functional connectivity in the basal ganglia network differentiates PD patients from controls. Neurology 2014;83(3):208-214.
98. Fling BW, Cohen RG, Mancini M, Nutt JG, Fair DA, Horak FB. Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. Brain 2013;136(8):2405-2418.
99. Helmich RC, Janssen MJR, Oyen WJG, Bloem BR, Toni I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol 2011;69(2):269-281.
100. Caligiore D, Pezzulo G, Baldassarre G, et al. Consensus paper: towards a systems-level view of cerebellar function: the interplay between cerebellum, basal ganglia, and cortex. Cerebellum 2016;16(1):203-229.
101. Garcia-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 2013;136(7):2120-2129.
102. Mak E, Su L, Williams GB, et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2015;138(10):2974-2986.
103. Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jiménez-Urbieta H, Rodriguez-Oroz MC. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease. Mov Disord 2016;31(6):861-881.
104. Olde Dubbelink KTE, Schoonheim MM, Deijen JB, Twisk JWR, Barkhof F, Berendse HW. Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology 2014;83(22):2046-2053.
105. Kostic VS, Agosta F, Petrovic I, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 2010;75(10):857-863.
106. Goldman JG, Stebbins GT, Dinh V, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain 2014;137(3):849-859.
107. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009;32(10):548-557.
108. Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10(9):797-805.
109. Adams JR. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005;128(12):2777-2785.
110. Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 2014;29(14):1767-1773.
111. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34(3):324-330.
112. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009;132(11):2970-2979.
113. de la Fuente-Fernández R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011;69(5):803-810.
114. Sossi V, de la Fuente-Fernandez Rl, Holden JE, Schulzer M, Ruth TJ, Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004;24(8):869-876.
115. de la Fuente-Fernandez R. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127(12):2747-2754.
116. Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest 2014;124(3):1340-1349.
117. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42(5):720-726.
118. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011;76(21):1811-1816.
119. Niccolini F, Foltynie T, Reis Marques T, et al. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. Brain 2015;138(10):3003-3015.
120. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-844.
121. Metter EJ, Riege WH, Kameyama M, Kuhl DE, Phelps ME. Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's, and Parkinson's diseases. J Cereb Blood Flow Metab 1984;4:500-506.
122. Pappata S, Santangelo G, Aarsland D, et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011;77(14):1357-1362.
123. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nuc Med 2011;52(6):848-855.
124. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71(12):903-910.
125. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79(12):1331-1338.
126. Sanchez-Contreras M, Heckman MG, Tacik P, et al. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2016;32(1):115-123.
127. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65(11):1716-1722.
128. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 2003;44(6):870-876.
129. Politis M, Wu K, Loane C, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010;75(21):1920-1927.
130. Remy P. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128(6):1314-1322.
131. Pavese N. Imaging the aetiology of sleep disorders in dementia and Parkinson's disease. Curr Neurol Neurosci Rep 2014;14(12):501.
132. Hilker R, Razai N, Ghaemi M, et al. [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. Clin Neurol Neurosurg 2003;105(4):262-269.
133. Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 2006;12(5):284-288.
134. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13(7):281-285.
135. Chevalier G, Deniau JM. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 1990;13(7):277-280.
136. Guridi J, Alegre M. Oscillatory activity in the basal ganglia and deep brain stimulation. Mov Disord 2016;32(1):64-69.
137. Piconi B, Hernandez L, Obeso JA, Calabresi P. Motor complications in Parkinson's disease: molecular and electrophysiological mechanisms of dyskinesias. Mov Disord 2017;32.
138. Neumann W-J, Degen K, Schneider G-H, et al. Subthalamic synchronized oscillatory activity correlates with motor impairment in patients with Parkinson's disease. Mov Disord 2016;31(11):1748-1751.
139. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2010;134(1):36-49.
140. Cagnan H, Duff EP, Brown P. The relative phases of basal ganglia activities dynamically shape effective connectivity in Parkinson's disease. Brain 2015;138(6):1667-1678.
141. Nambu A. A new dynamic model of the cortico-basal ganglia loop. Prog Brain Res 2004;143:461-466.
142. Smith Y, Galvan A, Ellender TJ, et al. The thalamostriatal system in normal and diseased states. Front Syst Neurosci 2014;8:5.
143. Hamani C, Lozano AM, Mazzone PAM, et al. Pedunculopontine nucleus region deep brain stimulation in Parkinson disease: surgical techniques, side effects, and postoperative imaging. Stereotact Funct Neurosurg 2016;94(5):307-319.
144. Panigrahi B, Martin KA, Li Y, et al. Dopamine is required for the neural representation and control of movement vigor. Cell 2015;162(6):1418-1430.
145. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990;27(3):276-282.
146. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 2013;80(22):2035-2041.
147. Tanner CM, Goldman SM, Ross GW, Grate SJ. The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk. Alzheimers Dement 2014;10(3):S213-S225.
148. Goldman SM. Environmental toxins and Parkinson's disease. Annu Rev Pharmacol Toxicol 2014;54(1):141-164.
149. Furlong M, Tanner CM, Goldman SM, et al. Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease. Environ Int 2015;75:144-150.
150. Weisskopf MG, Knekt P, O'Reilly EJ, et al. Polychlorinated biphenyls in prospectively collected serum and Parkinson's disease risk. Mov Disord 2012;27(13):1659-1665.
151. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007;64(7):990-997.
152. Hancock DB, Martin ER, Fujiwara K, et al. NOS2A and the modulating effect of cigarette smoking in Parkinson's disease. Ann Neurol 2006;60(3):366-373.
153. Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord 2012;27(10):1276-1282.
154. Yamada-Fowler N, Söderkvist P. Coffee, genetic variants, and Parkinson's disease: gene–environment interactions. J Caffeine Res 2015;5(1):3-10.
155. Nussbaum RL. Genetics of synucleinopathies. Cold Spring Harb Perspect Med 2017:a024109.
156. Marras C, Lang A, van de Warrenburg BP, et al. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and Movement Disorder Society Task Force. Mov Disord 2016;31(4):436-457.
157. Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 2016;17(4):251-260.
158. Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44(4):595-600.
159. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4):601-607.
160. Brice A. Genetics of Parkinson's disease: LRRK2 on the rise. Brain 2005;128(12):2760-2762.
161. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7(7):583-590.
162. Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011;89(1):162-167.
163. Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011;89(1):168-175.
164. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 2014;29(4):454-462.
165. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46(9):989-993.
166. Vanhauwaert R, Verstreken P. Flies with Parkinson's disease. Exp Neurol 2015;274:42-51.
167. Vos M, Esposito G, Edirisinghe JN, et al. Vitamin K2 is a mitochondrial electron carrier that rescues Pink1 deficiency. Science 2012;336(6086):1306-1310.
168. Olgiati S, Quadri M, Bonifati V. Genetics of movement disorders in the next-generation sequencing era. Mov Disord 2016;31(4):458-470.
169. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276(7):374-379.
170. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21(4):343-354.
171. Lotia M, Jankovic J. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother 2016;17(7):895-909.
172. Freitas ME, Ruiz-Lopez M, Fox SH. Novel levodopa formulations for Parkinson's disease. CNS Drug 2016;30(11):1079-1095.
173. LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology 2016;86(14 suppl. 1):S3-S12.
174. Olanow CW. Levodopa: effect on cell death and the natural history of Parkinson's disease. Mov Disord 2014;30(1):37-44.
175. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-2508.
176. Jankovic J, Bressman S, Dauer W, Kang U. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Mov Disord 2015;30(1):1862-1869.
177. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs 2016;76(7):759-777.
178. Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord 2014;30(1):80-89.
179. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39(1):37-45.
180. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7(2):117-124.
181. Myers RH. Surgical procedure for postencephalitic tremor, with notes on the physiology of the premotor fibers. Arch Neurol Psychiatry 1940;44:445-459.
182. Cooper IS. Ligation of the anterior choroidal artery for involuntary movements; parkinsonism. Psychiatr Q 1953;27(2):317-319.
183. Cooper IS, Bravo G. Chemopallidectomy and chemothalamectomy. J Neurosurg 1958;15(3):244-250.
184. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992;76(1):53-61.
185. Svennilson E, Torvik A, Lowe R, Leksell L. Treatment of parkinsonism by stereotactic thermolesions in the pallidal region. A clinical evaluation of 81 cases. Acta Psychiatrica Scandinavica 1960;35(3):358-377.
186. Rowland NC, Sammartino F, Lozano AM. Advances in surgery for movement disorders. Mov Disord 2016;32(1):5-10.
187. Pollak P, Benabid AL, Gross C, et al. [Effects of the stimulation of the subthalamic nucleus in Parkinson disease]. Rev Neurol (Paris) 1993;149(3):175-176.
188. Bishop MP, Elder ST, Heath RG. Intracranial self-stimulation in man. Science 1963;140(3565):394-396.
189. Lozano AM, Lipsman N. Probing and regulating dysfunctional circuits using deep brain stimulation. Neuron 2013;77(3):406-424.
190. Meyers R, Fry WJ, Fry FJ, Dreyer LL, Schultz DF, Noyes RF. Early experiences with ultrasonic irradiation of the pallidofugal and nigral complexes in hyperkinetic and hypertonic disorders. J Neurosurg 1959;16(1):32-54.
191. Lipsman N, Schwartz ML, Huang Y, et al. MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. Lancet Neurol 2013;12(5):462-468.
192. Elias WJ, Lipsman N, Ondo WG, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2016;375(8):730-739.
193. Weintraub D, Elias WJ. Focus ultrasound therapy for movement disorders: current data and expected developments. Mov Disord 2017;32:20-27.
194. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on tremor. Mov Disord 2008;13(S3):2-23.
195. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006;67(9):1612-1617.
196. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-184.
197. Qamhawi Z, Towey D, Shah B, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain 2015;138(10):2964-2973.
198. Hirsch E. Dopamine, tremor, and Parkinson's disease. Lancet 1992;340(8811):125-126.
199. Jellinger KA. Post mortem studies in Parkinson's disease—is it possible to detect brain areas for specific symptoms? J Neural Transm 1999;56:1-29.
200. Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L. Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov Disord 2011;26:416-423.
201. Isaias IU, Marzegan A, Pezzoli G, et al. A role for locus coeruleus in Parkinson tremor. Front Hum Neurosci 2012;5:179.
202. Raz A, Vaadia E, Bergman H. Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. J Neurosci 2000;20(22):8559-8571.
203. Muthuraman M, Heute U, Arning K, et al. Oscillating central motor networks in pathological tremors and voluntary movements. What makes the difference? NeuroImage 2012;60(2):1331-1339.
204. Mure H, Hirano S, Tang CC, et al. Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects. NeuroImage 2011;54(2):1244-1253.
205. Bergman H, Deuschl GN. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord 2002;17(S3):S28-S40.
206. Rivlin-Etzion M, Marmor O, Heimer G, Raz A, Nini A, Bergman H. Basal ganglia oscillations and pathophysiology of movement disorders. Curr Opin Neurobiol 2006;16(6):629-637.
207. Llinas R. The intrinsic electrophysiological properties of mammalian neurons: insights into central nervous system function. Science 1988;242(4886):1654-1664.
208. Zirh TA, Lenz FA, Reich SG, Dougherty PM. Patterns of bursting occurring in thalamic cells during parkinsonian tremor. Neuroscience 1998;83(1):107-121.
209. Plenz D, Kital ST. A basal ganglia pacemaker formed by the subthalamic nucleus and dexternal globus pallidus. Nature 1999;400(6745):677-682.
210. Bar-Gad I, Heimer G, Ritov Y, Bergman H. Functional correlations between neighboring neurons in the primate globus pallidus are weak or nonexistent. J Neurosci 2003;23(10):4012-4016.
211. Dickson DW. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012;2(8):a009258-a009258.
212. Rajput AH, Rajput A. Accuracy of Parkinson disease diagnosis unchanged in 2 decades. Neurology 2014;83(5):386-387.
213. Papadimitriou D, Antonelou R, Miligkos M, et al. Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a longitudinal study. Mov Disord 2016;31(8):1226-1230.
214. Vilensky JA, Gilman S, McCall S. A historical analysis of the relationship between encephalitis lethargica and postencephalitic parkinsonism: a complex rather than a direct relationship. Mov Disord 2010;25(9):1116-1123.
215. Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord 2015;30(6):780-785.
216. Kasten M, Klein C. Genetic risk loci for Parkinson's disease: moving from state to trait? Mov Disord 2015;30(6):747-749.
217. Kumaran R, Cookson MR. Pathways to parkinsonism redux: convergent pathobiological mechanisms in genetics of Parkinson's disease. Hum Mol Genet 2015;24(R1):R32-R44.
218. Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson's disease. Mov Disord 2012;27(1):54-60.
219. Berg D, Lang AE, Postuma RB, et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 2013;12(5):514-524.
220. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(5):2283-2301.
221. Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012;135(6):1860-1870.
222. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119(6):689-702.
223. Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 2012;27(5):656-665.
224. Hasmann SE, Berg D, Hobert MA, et al. Instrumented Functional Reach Test Differentiates Individuals at High Risk for Parkinsons™ disease from controls. Front Aging Neurosci 2014;6:286.
225. Sánchez-Ferro Á, Elshehabi M, Godinho C, et al. New methods for the assessment of Parkinson's disease (2005 to 2015): a systematic review. Mov Disord 2016;31(9):1283-1292.
226. Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord 2012;27(7):913-916.
227. Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 2015;77(5):830-839.
228. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013;14(8):744-748.
229. Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS ONE 2014;9(2):e89741.
230. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005;65(9):1442-1446.
231. Postuma RB, Gagnon J-F, Vendette M, Desjardins C, Montplaisir JY. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 2011;69(5):811-818.
232. Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension. Neurology 2015;85(16):1362-1367.
233. Gustafsson H, Nordstrom A, Nordstrom P. Depression and subsequent risk of Parkinson disease: a nationwide cohort study. Neurology 2015;84(24):2422-2429.
234. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011;76(10):863-869.
235. Vilas D, Shaw LM, Taylor P, et al. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. Mov Disord 2016;31(6):906-914.
236. Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 2014;83(19):1739-1746.
237. Jennings D, Stern M, Siderowf A, Eberly S, Oakes D, Marek K. Longitudinal imaging and phenoconversion in the PARS Prodromal Cohort [abstract]. 2015;30(suppl. 1):998.
238. Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol 2016;79(6):940-949.
239. Vilas D, Iranzo A, Tolosa E, et al. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol 2016;15(7):708-718.
240. Gruschus JM. Did α-synuclein and glucocerebrosidase coevolve? Implications for Parkinson's disease. PLoS ONE 2015;10(7):e0133863.
241. Singleton AB. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302(5646):841.
242. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-840.
243. Milber JM, Noorigian JV, Morley JF, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 2012;79(24):2307-2314.
244. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008;70(13):1042-1048.
245. Moors T, Paciotti S, Chiasserini D, et al. Lysosomal dysfunction and α-synuclein aggregation in Parkinson's disease: diagnostic links. Mov Disord 2016;31(6):791-801.
246. Xilouri M, Brekk OR, Stefanis L. Autophagy and alpha-synuclein: relevance to Parkinson's disease and related synucleopathies. Mov Disord 2016;31(2):178-192.
247. Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. IUBMB Life 2001;52(3-5):135-141.
248. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino P-G. Lessons from the rotenone model of Parkinson's disease. Trends Pharmacol Sci 2010;31(4):141-142.
249. Cantuti-Castelvetri I, Lin MT, Zheng K, et al. Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging 2005;26(10):1343-1355.
250. Giannoccaro MP, La Morgia C, Rizzo G, Carelli V. Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease. Mov Disord 2017;32(3):346-363.
251. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14(5):504-506.
252. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RKB. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α-synuclein staging. Neuropathol Appl Neurobiol 2008;34:284-295.
253. Halliday G, McCann H, Shepherd C. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Expert Rev Neurother 2012;12:673-686.
254. Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017;18(2):101-113.
255. Kordower JH, Brundin P. Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another? Neuropsychopharmacology 2009;34(1):254.
256. Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem 2012;288(15):10736-10741.
257. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007;30:244-250.
258. Mosharov EV, Larsen KE, Kanter E, et al. Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 2009;62(2):218-229.
259. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008;23:474-483.
260. Zucca FA, Segura-Aguilar J, Ferrari E, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol 2017;155:96-119.
261. Li J-Y, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14(5):501-503.
262. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2011;27(1):8-30.
263. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106(31):13010-13015.
264. Luk KC, Song C, O'Brien P, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009;106(47):20051-20056.
265. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011;72(1):57-71.
266. Olanow CW. Do prions cause Parkinson disease? The evidence accumulates. Ann Neurol 2014;75(3):331-333.
267. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012;27(6):716-719.
268. Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord 2013;28:31-40.
269. Olanow CW, Kordower JH. Targeting α-synuclein as a therapy for Parkinson's disease: the battle begins. Mov Disord 2017;32(2):203-207.
270. Schapira AHV. Science, medicine, and the future: Parkinson's disease. BMJ 1999;318(7179):311-314.
271. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321(20):1364-1371.
272. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-1278.
273. Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71(2):141-150.
274. Schapira AHV, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013;12(8):747-755.
275. Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinson's disease. Mov Disord 2013;28(1):96-109.
276. Collier TJ. Rebuilding the nigrostriatal dopamine pathway: 30 years and counting. Exp Neurol 2014;256:21-24.
277. Lapchak PA, Araujo DM, Hilt DC, et al. Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. Brain Res 1998;789(1):9-22.
278. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60(1):69-73.
279. Kordower JH, Palfi S, Chen E-Y, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46(3):419-424.
280. Kordower JH. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290(5492):767-773.
281. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2007;59(3):459-466.
282. Bartus RT, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol Aging 2013;34(1):35-61.
283. Marks WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7(5):400-408.
284. Warren OC, Bartus RT, Baumann TL, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 2015;78(2):248-257.
285. Dehay B, Vila M, Bezard E, Brundin P, Kordower JH. Alpha-synuclein propagation: new insights from animal models. Mov Disord 2015;31(2):161-168.
286. Collier TJ, Redmond DE, Steece-Collier K, Lipton JW, Manfredsson FP. Is alpha-synuclein loss-of-function a contributor to parkinsonian pathology? Evidence from non-human primates. Front Neurosci 2016;10:12.
287. Bergström A-L, Kallunki P, Fog K. Development of passive Immunotherapies for synucleinopathies. Mov Disord 2015;31(2):203-213.
288. McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA. α-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 2010;5(8):e12122.
289. Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 2014;34(28):9441-9454.
290. Diogenes MJ, Dias RB, Rombo DM, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012;32(34):11750-11762.
291. Tozzi A, de Iure A, Bagetta V, et al. Alpha-synuclein produces early behavioral alterations via striatal cholinergic synaptic dysfunction by interacting with GluN2D N-methyl-D-aspartate receptor subunit. Biol Psychiatry 2016;79(5):402-414.
292. Gegg ME, Burke D, Heales SJR, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012;72(3):455-463.
293. Schapira AHV, Gegg ME. Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci U S A 2013;110(9):3214-3215.
294. McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014;137(5):1481-1495.
295. Olanow CW, Kieburtz K, Schapira AHV. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 2009;64(S2):S101-S110.
296. Calabresi P, Di Filippo M. Multitarget disease-modifying therapy in Parkinson's disease? Lancet Neurol 2015;14(10):975-976.
297. Schapira AHV, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 2014;384(9942):545-555.
298. Chaudhuri KR, Jenner P. 200 years since James Parkinson's essay on “The Shaking Palsy” Have we made progress? Mov Disord 2017;32.
299. Payami H. The emerging science of precision medicine and pharmacogenomics for Parkinson's disease. Mov Disord 2017;32.